Sign in

Joris van de Haar, MD, PhD

@joris-vd-haar.bsky.social
3.7K followers 1.4K following 147 posts

Clinician-scientist / precision medicine / cancer immunology / bioinformatics / MD, PhD @Netherlands Cancer Institute / ESMO precision medicine working group Trying to have fun discovering stuff to help patients. Opinions are my own.

PostsRepliesMedia
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 15/02/2026
Postdoc alert in spatial biology! Building upon our previous work with MSI cancers (e.g. de Vries et al, Nature, 2023), the Voest Group at the NKI is hiring a (fully funded) postdoctoral fellow with strong expertise in spatial cancer biology. Learn more / apply here: www.nki.nl/careers-stud...
nki.nl
Computational Postdoc | Netherlands Cancer Institute
Computational Postdoc Voest Lab (fully funded) — Spatial Decoding of Unconventional Antitumor Immunity in Colorectal Cancer
31113
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 30/10/2025
🚀 We’re hiring! Join our team at the NKI as a Postdoc, using Quantitative Membrane Proteomics to design novel cancer immunotherapies! Best of two worlds from the Voest and Lindeboom Labs. Cutting-edge proteomics, translational immunotherapy and world-class instrumentation? let’s connect! 🔬💡
142
Reposted by Joris van de Haar, MD, PhD
Fran Martínez-Jiménez @franmj88.bsky.social · 04/10/2025
🚨 International Postdoctoral Positions Open at VHIO! 🚨 The VHIO VIDA Postdoctoral Program is now open! We’re a fully funded position for international postdocs to work on cutting-edge exciting projects, develop professionally, and pave the way toward independence. 👉 vhiovidaprogramme.eu
vhiovidaprogramme.eu
Home - VIDA
045
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 16/07/2025
Very cool study! A very logical explanation for the fundamental question how non-stem cells “know” they need to become one after tissue damage. And is this deregulated in cancer?
140
Reposted by Joris van de Haar, MD, PhD
Danielle Bianchi @daaninthelab.bsky.social · 04/07/2025
In today’s publication in Science we introduce Zincore: a novel protein of QRICH1 and SEPHS1 and functions as a transcriptional coregulator dedicated to zinc finger transcription factors. Here’s how we found it: 🧵 www.science.org/doi/10.1126/... 1/11
science.org
Zincore, an atypical coregulator, binds zinc finger transcription factors to control gene expression
Zinc finger proteins (ZNFs) are the largest family of transcription factors, yet how they activate gene expression remains unclear. In this study, we identified Zincore, a protein complex consisting o...
313148
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 05/05/2025
Important work towards one of the holy grails in cancer immunotherapy: understanding/predicting/designing TCR specificities
051
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 07/04/2025
Read our ESMO recommendations on MTBs for precision medicine here: www.sciencedirect.com/science/arti...
sciencedirect.com
ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice
With an increased uptake of genomic profiling in clinical practice and the evolving complexity of diagnostic modalities, vast amounts of complex data …
050
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 17/02/2025
Highly recommended!
111
Reposted by Joris van de Haar, MD, PhD
Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · 17/02/2025
We are hiring! www.nki.nl/careers-stud... @nkinl.bsky.social
nki.nl
Bioinformatician in Breast Cancer Immunology | Netherlands Cancer Institute
14219
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 08/02/2025
🤙🤙🤙 Precision oncology starter package
000
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 08/02/2025
We live in exciting times www.nejm.org/doi/full/10....
nejm.org
Xenotransplantation of a Porcine Kidney for End-Stage Kidney Disease | NEJM
Xenotransplantation offers a potential solution to the organ shortage crisis. A 62-year-old hemodialysis-dependent man with long-standing diabetes, advanced vasculopathy, and marked dialysis-access...
000
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 04/02/2025
Cool concept
174
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 03/02/2025
Imagine how many black and white pictures could have been published in full color
020
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 27/01/2025
Magnificent work from Monika Wolkers and team : γδ T cells are the prime anti-tumoral T cells in pediatric neuroblastoma Another case where γδ T cells are the central effectors of anticancer immunity. www.biorxiv.org/content/10.1... @forum-gd.bsky.social
biorxiv.org
γδ T cells are the prime anti-tumoral T cells in pediatric neuroblastoma
High-risk pediatric neuroblastoma patients have a dismal survival rate despite intensive treatment regimens. New treatment options are thus required. Even though HLA expression in neuroblastoma is low and immune cell infiltrates are limited, the presence of tumor infiltrating lymphocytes (TILs) is indicative for better patient survival. Here, we show that most tumor lesions contain viable immune cell infiltrates after induction chemotherapy, with high percentages of CD3+ T cells. We therefore expanded the TILs and tested their anti-tumoral activity. With sufficient starting material, TIL expansion was as efficient as for adult solid tumors. However, whereas TIL products from adult tumors almost exclusively contained αβ T cells, in neuroblastoma-derived TILs, γδ T cells expanded with similar efficacy as αβ T cells. Importantly, the anti-tumor responses in response to autologous tumor digest primarily originated from (Vδ1- and Vδ3-expressing) γδ T cells, and not from αβ T cells. In conclusion, this finding creates a window of opportunity for immunotherapy for neuroblastoma patients, with γδ T cells as potential prime responders. ### Competing Interest Statement The authors have declared no competing interest.
0103
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 22/01/2025
Big if true: do cancer cells transfer mutated mitochondria into tumor infiltrating lymphocytes to impair their function? mtDNA is challenging to work with, so looking forward to see this finding confirmed. But cool concept and big congrats to the authors! www.nature.com/articles/s41...
nature.com
Immune evasion through mitochondrial transfer in the tumour microenvironment - Nature
Mitochondria with mutations in their DNA from cancer cells can be transferred to T cells in the tumour microenvironment, which leads to T cell dysfunction and impaired antitumour immunity.
0102
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 08/01/2025
1/2 Puzzling result from the DRUP study: the more mutations driving proliferation in a tumor, the less effect of targeting only one of them with specific drugs. www.esmoopen.com/article/S205...
esmoopen.com
DEFINE_ME
130
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 05/01/2025
Bizarre story. Genetic Analysis of a Sarcoma Accidentally Transplanted from a Patient to a Surgeon | New England Journal of Medicine www.nejm.org/doi/full/10....
nejm.org
Genetic Analysis of a Sarcoma Accidentally Transplanted from a Patient to a Surgeon | NEJM
Modern concepts of cancer immunology originated from the classic observations by Jensen, Loeb, Tyzzer, and Little in the early years of the 20th century of the rejection of transplanted allogeneic ...
0114
Reposted by Joris van de Haar, MD, PhD
Mike @empiricgame.bsky.social · 14/12/2024
Forget Die Hard vancomycin is a Christmas antibiotic
Vancomycin colored over to be a 🎄
314032
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 13/12/2024
Awesome www.nature.com/immersive/d4...
nature.com
The best science images of 2024 — Nature’s picks
A breathtaking total eclipse, courageous penguins, volcanic smoke rings and more.
021
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 13/12/2024
Impressive www.science.org/content/arti...
science.org
Science’s 2024 Breakthrough of the Year: Opening the door to a new era of HIV prevention
A drug with a novel mechanism protects people against the AIDS virus for 6 months. It could speed the end of the epidemic—if those who need it most get access
012
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 13/12/2024
🤩🤩🤩 www.nature.com/articles/s41...
nature.com
Eleven clinical trials that will shape medicine in 2025 - Nature Medicine
Nature Medicine asks leading researchers to name their top clinical trial for 2025, from gene therapies for prion disease and sickle-cell disease to digital tools for cancer and mental health.
000
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 09/12/2024
I'm pleased to share that I will be speaking at the Clinical Cancer Genomics meeting, taking place on the 20th-21st of March 2025 in Amsterdam. Register now to join me and discuss the latest developments with leading experts in the field: www.ccg2025.eu #CCG2025
0101
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 09/12/2024
Looking forward to speaking at the Clinical Cancer Genomics conference on March 20-21, 2025 in Amsterdam. Very nice and inspiring program with many European heavyweights, inc Edwin & many others. Register via the link below!👇
040
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 09/12/2024
Prenatal cfDNA Sequencing and Incidental Detection of Maternal Cancer | New England Journal of Medicine www.nejm.org/doi/full/10....
nejm.org
Prenatal cfDNA Sequencing and Incidental Detection of Maternal Cancer | NEJM
Cell-free DNA (cfDNA) sequence analysis to screen for fetal aneuploidy can incidentally detect maternal cancer. Additional data are needed to identify DNA-sequencing patterns and other biomarkers t...
040
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 06/12/2024
Some cool novel concepts: Nat biotech: platelets for targeted degrader delivery www.nature.com/articles/s41... Science: T cells for targeted drug delivery www.science.org/doi/10.1126/... www.science.org/doi/10.1126/... www.science.org/doi/10.1126/...
nature.com
Engineered platelets as targeted protein degraders and application to breast cancer models - Nature Biotechnology
Protein degradation is targeted to disease sites using engineered platelets.
0110
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 05/12/2024
Beautiful study by Jacco van Rheenen, Colinda Scheele & team about the impact of the menstrual cycle on neoadjuvant chemotherapy in young women with breast cancer. Cutting-edge fundamental science with direct implications for women and families @nkinl.bsky.social www.nature.com/articles/s41...
nature.com
The oestrous cycle stage affects mammary tumour sensitivity to chemotherapy - Nature
In three mouse models of breast cancer, we show reduced responses to neoadjuvant chemotherapy when treatment is initiated during the dioestrus stage, when compared with initiation during the oestrus s...
1346
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 03/12/2024
All 2024 changes in precision oncology beautifully outlined👇🚨 aacrjournals.org/cancerdiscov...
aacrjournals.org
Precision Oncology: 2024 in Review
Summary:. This article discusses the specific advances made in precision oncology in 2024. We comment on the evolving nature of predictive molecular events used to select patients who will most benefi...
031
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 03/12/2024
Interesting read👏👏👏 aacrjournals.org/cancerdiscov...
aacrjournals.org
Reflections on Advances in Cancer Research in 2024
There have been many impactful advances in basic, translational, and clinical cancer research in 2024. An important mission of Cancer Discovery is to ensure the timely dissemination of innovative ways...
051
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 02/12/2024
Any new 🦋 arrivals? go.bsky.app/xg4Y26
8163
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 02/12/2024
Any recent 🦋 arrivals?
030
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 01/12/2024
Powerhouse 🤩
030
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 01/12/2024
1/3 In this week’s NEJM: Andre et al report very positive results of dual ICB in MSI cancers. Logical, right? But why is this very interesting from an immunological point of view? About 75% lacks HLA class I. Likely innate immune mechanisms are centrally involved dx.doi.org/10.1158/1078...
dx.doi.org
The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol
AbstractPurpose:. The treatment efficacy of nivolumab was evaluated in patients with advanced, treatment-refractory solid mismatch repair deficiency/microsatellite-instable (dMMR/MSI) tumors, and in-d...
1246
Reposted by Joris van de Haar, MD, PhD
Marcos Malumbres @mmalumbres.bsky.social · 27/11/2024
Exciting news in cancer therapy! The order of drugs impacts the duration of treatment, toxicity, and economic cost. A necessary example of how relevant academic, self-funded trials are!! Breast #cancer #oncosky #oncsky #medsky 🧪 @natureportfolio.bsky.social www.nature.com/articles/d41...
nature.com
Toxicity and costs of cancer treatment reduced by deferring CDK4/6 inhibitor use
No difference in survival outcomes between use of CDK4/6 inhibitors as first- or second-line treatment in metastatic breast cancer.
15614
Reposted by Joris van de Haar, MD, PhD
Anna Obenauf @obenaufa.bsky.social · 27/11/2024
1/23 Big news for the #ObenaufLab! So excited to finally share our new study providing another puzzle piece, why immunotherapy fails in many tumors, now out in @Nature 🧵👇 www.nature.com/articles/s41...
47559142
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 27/11/2024
Great great work!!👏👏👏
070
Reposted by Joris van de Haar, MD, PhD
Netherlands Cancer Institute @nkinl.bsky.social · 27/11/2024
Delaying and shortening the duration of treatment with CDK4/6 inhibitors in patients with metastatic breast cancer leads to similar survival outcomes while reducing toxicity and achieving substantial cost savings, the SONIA trial shows. Read more ➡️ bit.ly/3Oqw7aX
04011
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 27/11/2024
Another great story about the relevance of IL-15 in cancer immunotherapy in todays Nature, complementing the work by @obenaufa.bsky.social and team www.nature.com/articles/s41...
nature.com
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers - Nature
We evaluate the effects in humans of interleukin-15 co-expression on glypican-3 (GPC3) chimeric antigen receptor (CAR) T cells and demonstrate that IL-15 increases the expansion, intratumoural su...
081
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 27/11/2024
Great investigator-initiated study by Gabe Sonke et al in Nature with big clinical impact! The SONIA trial. Better and cheaper care at the same time👌 www.nature.com/articles/s41...
nature.com
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer - Nature
The phase 3 SONIA trial challenges the benefits of using cyclin-dependent kinase 4 and 6 inhibitors as a first-line compared with second-line treatment.
040
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 27/11/2024
Beautiful work by @obenaufa.bsky.social and team, looking beyond CD8 T cells. The immune system is a system after all… Important role of monocytes expressing key molecules incl IL-15 and CXCL9. And a targetable pathway via prostaglandins to improve immunotherapy.👏👏👏 www.nature.com/articles/s41...
nature.com
0131
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 26/11/2024
Very exciting stuff🔥 Will PROTAC protein degraders elicit a new innovative wave in cancer drug development? Nearly endless possibilities🤩 www.nature.com/articles/d41...
nature.com
PROTAC protein degraders to drug the undruggable enter phase 3 trials
Pharmaceutical companies are investing in therapies that target proteins for degradation, with trials ongoing for cancer, autoimmune diseases and neurological disorders.
1122
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 26/11/2024
🔥🔥🔥👇😀
030
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 26/11/2024
Very well-deserved recognition of a great leader and inspiration! Proud to work at @nkinl.bsky.social
040
Reposted by Joris van de Haar, MD, PhD
Jon Lim, FRCP PhD @drjonlim.bsky.social · 25/11/2024
🧑‍🔬🏛️👩‍⚕️ Lots of our #CancerImmunology community now here 🦋, including @jimallisonphd.bsky.social 🏅! #AcademicSky #ImmunoSky #OncSky #StarterPack 1 is already full 🙌, so starting a another one. Let's continue growing! - Pack 1️⃣: go.bsky.app/PRdmHCP - Pack 2️⃣: go.bsky.app/93eqJbs
205017
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 25/11/2024
Cool R-based analysis of your BlueSky followers🦋 Which accounts are repeatedly followed by your followers? The nice thing of BlueSky being an open protocol🔓
030
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 24/11/2024
BlueSky hack 🦋 Browse all starter packs here 🎉 blueskydirectory.com/starter-pack...
blueskydirectory.com
Bluesky Starter Packs - Bluesky Directory
Browse a list of Bluesky Starter Packs. Discover and connect with your community on Bluesky
030
Reposted by Joris van de Haar, MD, PhD
Johanna Joyce @johannajoyce.bsky.social · 23/11/2024
Both #Cancer #Research starter packs are now completely full! ~300 researchers, oncologists, students, postdocs, patient advocates, and organizations supporting cancer research 🧪🔬⚕️ I hope you'll find these useful to build our community here Pack 1: go.bsky.app/FEoaJMc Pack 2: go.bsky.app/6EcjWNA
3224388
Reposted by Joris van de Haar, MD, PhD
Joanna Bagniewska @joannabagniewska.com · 22/11/2024
Why do insects fly around artificial lights? They don't actually want to fly towards them, they just can't really get away from them. Insects naturally tilt their dorsum towards a light source, and as a result end up flying around it in circles, trapped. 🧪 🦋 www.nature.com/articles/s41...
nature.com
Why flying insects gather at artificial light - Nature Communications
It is unclear why flying insects congregate around artificial light sources. Here, the authors use high-speed videography and motion-capture, finding that insects fly perpendicular to light sourc...
13371103
Reposted by Joris van de Haar, MD, PhD
ACIR @acir-org.bsky.social · 22/11/2024
IL-15 is a key player in immune responses but has faced toxicity challenges in clinical trials. Huntington’s innovative approach focuses on enhancing tumor-specific IL-15 activity by preventing receptor degradation, avoiding harmful systemic effects. #Immunotherapy acir.org/weekly-dige...
031
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 22/11/2024
Fascinating data. What would underly this? Especially huge (50%) difference in colitis; as noted this may make sense given more freq sporadic IBD and coeliac disease in White pts. But also many AI diseases more freq in Black pts which do not translate into irAEs www.thelancet.com/journals/lan...
thelancet.com
Effectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort study
Compared with White patients, Black patients had similar ICI effectiveness and lower toxicities among those treated in the national VHA system, potentially reflecting an important difference in the th...
130
Joris van de Haar, MD, PhD @joris-vd-haar.bsky.social · 22/11/2024
No cancer research but pretty cool. The world’s first saber-toothed cat mummy has been found in Siberia www.nationalgeographic.com/science/arti... via @NatGeo
nationalgeographic.com
The world’s first saber-toothed cat mummy has been found in Siberia
This remarkably well-preserved cub could help scientists answer questions about sabertooth anatomy, hunting, and even coat color.
042